Actelion Ltd. is a global biopharmaceutical company headquartered in Allschwil / Basel, Switzerland. Actelion focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs. With a team of 2410 pharmaceutical professionals, Actelion has subsidiaries in more than 25 countries.
Actelion Pharmaceuticals Canada inc. is actively involved in various therapeutic areas including respirology, rheumatology and cardiology. In December 2001, Actelion launched the first oral endothelin-receptor antagonist, Tracleer, for the treatment of pulmonary arterial hypertension.
Today, Actelion Canada is pleased to offer an innovative solution to the Canadian dermatology community, Toctino (alitreinoin), for their patients suffering from chronic hand eczema (CHE).